Spop-binding bifunctional degraders: a novel approach for cancer immunotherapy
{{output}}
Introduction: Current PD-L1 degraders, whether antibody-based or small-molecule-mediated, are hindered by limitations in pharmacokinetics (e.g., poor tissue penetration) or pharmacodynamics (e.g., suboptimal degradation efficacy,... ...
